A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Must have received: anti-myeloma treatment

treated with at least 3 (Part 1) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2)

Cannot have received: (alnuctamab)

Exception: Arm A only

Prior treatment with alnuctamab (Arm A)

Cannot have received: (mezigdomide)

Exception: Arm B only

Prior treatment with mezigdomide (Arm B)

Cannot have received: (iberdomide)

Exception: Arm C only

Prior treatment with iberdomide (Arm C)

Cannot have received: (elranatamab)

Exception: Arm D only

Prior treatment with elranatamab (Arm D)

Cannot have received: BCMA-targeting therapy

Exception: Part 2 Arms A and D only

Prior treatment with BCMA-targeting therapy (Part 2 Arms A and D)

Cannot have received: GPRC5D-targeting therapy

Prior treatment with GPRC5D-targeting therapies